Literature DB >> 7220886

Complete myelographic evaluation of spinal metastases from medulloblastoma.

R H Dorwart, W M Wara, D Norman, V A Levin.   

Abstract

Twenty-six patients with medulloblastoma had complete myelography and spinal fluid cytology and tests for polyamine levels in the evaluation for spinal metastases. The nature and location of abnormalities are presented in this report. Metrizamide was demonstrated to be safe and effective for complete myelography in children. The usefulness of myelography in detecting spinal metastases at the time of initial diagnosis (11%) and at the time of first intracranial recurrence (33%) is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7220886     DOI: 10.1148/radiology.139.2.7220886

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Medulloblastomas in childhood: postsurgical evaluation with myelography and cerebrospinal fluid cytology.

Authors:  A M Flannery; T Tomita; M Radkowski; D G McLone
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

2.  A new staging method versus TNM staging in children with posterior fossa primitive neuroectodermal tumor (medulloblastoma).

Authors:  J P Laurent; W R Cheek
Journal:  Childs Nerv Syst       Date:  1986       Impact factor: 1.475

3.  Red blood cell polyamines as a diagnostic indicator of glioma presence and recurrence.

Authors:  P Elworthy; E Hitchcock
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

4.  Spread of blood in cerebrospinal fluid following craniotomy simulates spinal metastases.

Authors:  S Cronqvist; D Greitz; P Maeder
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

Review 5.  Current diagnostic and therapeutic management of CNS metastasis in childhood primitive neuroectodermal tumors and ependymomas.

Authors:  W Scheurlen; J Kühl
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.